AlloVir, Inc. ALVR NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

47/100

1/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

AlloVir, Inc. (ALVR) .

本页证实的标准:

VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。

SharesGrow 综合评分： 44/100 其中 1/7 项标准通过。

SharesGrow 7-Criteria Score

47/100

SG Score

View full scorecard →

—

价值

N/A

No coverage

未來

40/100

Analyst consensus

→ Forecast

✗

过去

0/100

→ Income

健康

67/100

Debt-to-Equity & liquidity

→ Health

✗

护城河

28/100

→ Income

✓

成长

100/100

→ Income

—

收入

N/A

No coverage

估值概览 — ALVR

估值倍数

P/E (TTM)0.0

前瞻 P/EN/A

PEG 比率N/A

前瞻 PEGN/A

P/B 比率0.00

P/S 比率0.00

EV/EBITDA0.0

每股数据

EPS (TTM)$-2.85

每股账面价值$0.00

每股营收$0.00

每股自由现金流$0.00

收益率与内在价值

盈利收益率N/A

股息收益率0.00%

EPS：实际 vs 预期

P/E Ratio & Earnings Yield

每股收益 (EPS) 历史

Year	EPS（稀释）	营收	净利润	净利润率
2018	$-79,765,000.00	$1.14M	$-2.43M	-214.1%
2019	$-16.93	$165K	$-23.84M	-14447.9%
2020	$-2.59	$0.00	$-69.78M	-
2021	$-2.74	$0.00	$-171.96M	-
2022	$-2.20	$0.00	$-168.71M	-
2023	$-1.83	$0.00	$-190.42M	-
2024	$-0.51	$0.00	$-58.77M	-
2025	$-2.85	$0.00	$-43.44M	-